Novel Formulation of Bortezomib for Multiple Myeloma May Improve Efficacy and Reduce Adverse Events
July 9th 2014Researchers at the Dana-Farber Cancer Institute and Brigham and Women's Hospital have tested a nanomedicine technology in mice formulated to precisely target myeloma cancer cells with a novel bortezomib delivery system.
Read More